US Retail Drug Spending Growth Slows Substantially In 2016
Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.
You may also be interested in...
Drop in number of prescriptions dispensed for opioids contributed to minimal spending growth for retail prescription drugs in 2017, according to latest CMS National Health Expenditures Report.
Actuaries with the US Centers for Medicare and Medicaid Services predict the share of retail prescription drug costs represented by manufacturer rebates will level off in the coming years, resulting in higher drug pricing trends across government and commercial insurance.
Government price negotiations, financial transparency in the drug supply chain and changes to orphan drug incentives would go a long way toward making drugs more affordable, a National Academies committee says in a new report; dissent authored by two pharma industry veterans warns of 'unintended consequences' if recommendations are implemented.